Enzymatica AB (publ) (STO:ENZY)
Sweden · Delayed Price · Currency is SEK 1.850
+0.025 (1.37%)
Feb 10, 2026, 5:15 PM CET
Enzymatica AB Revenue
Enzymatica AB had revenue of 15.01M SEK in the quarter ending September 30, 2025, with 19.43% growth. This brings the company's revenue in the last twelve months to 52.73M, up 19.17% year-over-year. In the year 2024, Enzymatica AB had annual revenue of 45.58M, down -10.47%.
Revenue (ttm)
52.73M
Revenue Growth
+19.17%
P/S Ratio
8.52
Revenue / Employee
2.51M
Employees
21
Market Cap
449.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.58M | -5.33M | -10.47% |
| Dec 31, 2023 | 50.90M | 1.96M | 4.00% |
| Dec 31, 2022 | 48.95M | -8.30M | -14.49% |
| Dec 31, 2021 | 57.24M | -54.00M | -48.54% |
| Dec 31, 2020 | 111.25M | 49.94M | 81.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 48.42M |
| Cereno Scientific AB | 46.66M |
| Newbury Pharmaceuticals AB | 36.76M |
| Nanexa AB | 31.92M |
| Orexo AB | 26.00M |
| Moberg Pharma AB | 12.50M |
| Klaria Pharma Holding AB (publ.) | 10.05M |